According to a report in The Legal Examiner, the new study published in Orthopedics indicates that testosterone replacement drugs can interact with thrombophilia, causing osteonecrosis and later, bone damage.
In the study, researchers examined patients who had been diagnosed with osteonecrosis after beginning testosterone therapy. The researchers honed in on the way testosterone drugs interacted with the previously undiagnosed thrombophilia of patients and determined that there was a correlation between testosterone replacement drugs and osteonecrosis.
According to The Legal Examiner, all federally filed testosterone replacement lawsuits were merged into a single court in the Northern District of Illinois in June 2014. Since the consolidation, thousands of lawsuits have entered the litigation. There are currently 3,500 cases pending.
Testosterone therapy patients that were diagnosed with osteonecrosis after taking the medication could be eligible to add a lawsuit to the thousands awaiting litigation with this newly demonstrated link between thrombophilia and osteonecrosis.
More articles on quality:
Vaginal seeding for C-section babies may not be completely safe
Academic medical centers often wait years before disclosing clinical trials results
4 key elements of early sepsis recognition and response
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
